Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles

Wei Zhang,1 Yunmei Song,1 Preethi Eldi,1 Xiuli Guo,2 John D Hayball,1,3 Sanjay Garg,1 Hugo Albrecht1 1Centre for Pharmaceutical Innovation and Development, Centre for Drug Discovery and Development, Experimental Therapeutics Laboratory, Sansom Institute for Health Research, School of Pharmacy and M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang W, Song Y, Eldi P, Guo X, Hayball JD, Garg S, Albrecht H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	ELP-GRP micelle liposome docetaxel prostate cancer Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/92e548053e514f939392d4a7ce8b8d73
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92e548053e514f939392d4a7ce8b8d73
record_format	dspace
spelling	oai:doaj.org-article:92e548053e514f939392d4a7ce8b8d732021-12-02T02:02:31ZTargeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles1178-2013https://doaj.org/article/92e548053e514f939392d4a7ce8b8d732018-01-01T00:00:00Zhttps://www.dovepress.com/targeting-prostate-cancer-cells-with-hybrid-elastin-like-polypeptideli-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Wei Zhang,1 Yunmei Song,1 Preethi Eldi,1 Xiuli Guo,2 John D Hayball,1,3 Sanjay Garg,1 Hugo Albrecht1 1Centre for Pharmaceutical Innovation and Development, Centre for Drug Discovery and Development, Experimental Therapeutics Laboratory, Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia; 2Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan, China; 3Robinson Research Institute and Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia Abstract: Prostate cancer cells frequently overexpress the gastrin-releasing peptide receptor, and various strategies have been applied in preclinical settings to target this receptor for the specific delivery of anticancer compounds. Recently, elastin-like polypeptide (ELP)-based self-assembling micelles with tethered GRP on the surface have been suggested to actively target prostate cancer cells. Poorly soluble chemotherapeutics such as docetaxel (DTX) can be loaded into the hydrophobic cores of ELP micelles, but only limited drug retention times have been achieved. Herein, we report the generation of hybrid ELP/liposome nanoparticles which self-assembled rapidly in response to temperature change, encapsulated DTX at high concentrations with slow release, displayed the GRP ligand on the surface, and specifically bound to GRP receptor expressing PC-3 cells as demonstrated by flow cytometry. This novel type of drug nanocarrier was successfully used to reduce cell viability of prostate cancer cells in vitro through the specific delivery of DTX. Keywords: ELP-GRP, micelle, liposome, docetaxel, prostate cancer, GRPR, GPCRZhang WSong YEldi PGuo XHayball JDGarg SAlbrecht HDove Medical PressarticleELP-GRPmicelleliposomedocetaxelprostate cancerMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 293-305 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	ELP-GRP micelle liposome docetaxel prostate cancer Medicine (General) R5-920
spellingShingle	ELP-GRP micelle liposome docetaxel prostate cancer Medicine (General) R5-920 Zhang W Song Y Eldi P Guo X Hayball JD Garg S Albrecht H Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles
description	Wei Zhang,1 Yunmei Song,1 Preethi Eldi,1 Xiuli Guo,2 John D Hayball,1,3 Sanjay Garg,1 Hugo Albrecht1 1Centre for Pharmaceutical Innovation and Development, Centre for Drug Discovery and Development, Experimental Therapeutics Laboratory, Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia; 2Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan, China; 3Robinson Research Institute and Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia Abstract: Prostate cancer cells frequently overexpress the gastrin-releasing peptide receptor, and various strategies have been applied in preclinical settings to target this receptor for the specific delivery of anticancer compounds. Recently, elastin-like polypeptide (ELP)-based self-assembling micelles with tethered GRP on the surface have been suggested to actively target prostate cancer cells. Poorly soluble chemotherapeutics such as docetaxel (DTX) can be loaded into the hydrophobic cores of ELP micelles, but only limited drug retention times have been achieved. Herein, we report the generation of hybrid ELP/liposome nanoparticles which self-assembled rapidly in response to temperature change, encapsulated DTX at high concentrations with slow release, displayed the GRP ligand on the surface, and specifically bound to GRP receptor expressing PC-3 cells as demonstrated by flow cytometry. This novel type of drug nanocarrier was successfully used to reduce cell viability of prostate cancer cells in vitro through the specific delivery of DTX. Keywords: ELP-GRP, micelle, liposome, docetaxel, prostate cancer, GRPR, GPCR
format	article
author	Zhang W Song Y Eldi P Guo X Hayball JD Garg S Albrecht H
author_facet	Zhang W Song Y Eldi P Guo X Hayball JD Garg S Albrecht H
author_sort	Zhang W
title	Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles
title_short	Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles
title_full	Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles
title_fullStr	Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles
title_full_unstemmed	Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles
title_sort	targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/92e548053e514f939392d4a7ce8b8d73
work_keys_str_mv	AT zhangw targetingprostatecancercellswithhybridelastinlikepolypeptideliposomenanoparticles AT songy targetingprostatecancercellswithhybridelastinlikepolypeptideliposomenanoparticles AT eldip targetingprostatecancercellswithhybridelastinlikepolypeptideliposomenanoparticles AT guox targetingprostatecancercellswithhybridelastinlikepolypeptideliposomenanoparticles AT hayballjd targetingprostatecancercellswithhybridelastinlikepolypeptideliposomenanoparticles AT gargs targetingprostatecancercellswithhybridelastinlikepolypeptideliposomenanoparticles AT albrechth targetingprostatecancercellswithhybridelastinlikepolypeptideliposomenanoparticles
_version_	1718402719980453888

Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles

Ejemplares similares